{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T12:34:36Z","timestamp":1791117276803,"version":"4.1.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2011,5,31]],"date-time":"2011-05-31T00:00:00Z","timestamp":1306800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institute of Health","doi-asserted-by":"publisher","award":["RO1-CA109053"],"award-info":[{"award-number":["RO1-CA109053"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institute of Health","doi-asserted-by":"publisher","award":["RO1-CA121115"],"award-info":[{"award-number":["RO1-CA121115"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007923","name":"UWCCC Investigator-Initiated","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007923","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction.<\/jats:title>\n                    <jats:p>Notch1 has been shown to be a tumor suppressor in neuroendocrine tumors (NETs). Previous in vitro studies in NET cell lines have also suggested that valproic acid (VPA), a histone deacetylase inhibitor, can induce Notch1 and that Notch1 activation correlates with a decrease in tumor markers for NETs. Thus, this study aimed to evaluate the role of VPA in treating NETs and to determine whether VPA induced the Notch signaling pathway signaling in vivo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods.<\/jats:title>\n                    <jats:p>Eight patients with low-grade NETs (carcinoid and pancreatic) were treated with 500 mg of oral VPA twice a day with dosing adjusted to maintain a goal VPA level between 50 and 100 \u03bcg\/mL. All patients were followed for 12 months or until disease progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>Notch1 signaling was absent in all tumors prior to treatment and was upregulated with VPA. One patient had an unconfirmed partial response and was noted to have a 40-fold increase in Notch1 mRNA levels. Four patients had stable disease as best response. Tumor markers improved in 5 out of 7 patients. Overall, treatment with VPA was well tolerated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion.<\/jats:title>\n                    <jats:p>VPA activates Notch1 signaling in vivo and may have a role in treating low-grade NETs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1634\/theoncologist.2011-0031","type":"journal-article","created":{"date-parts":[[2011,6,3]],"date-time":"2011-06-03T01:34:29Z","timestamp":1307064869000},"page":"835-843","source":"Crossref","is-referenced-by-count":73,"title":["A Pilot Phase II Study of Valproic Acid for Treatment of Low-Grade Neuroendocrine Carcinoma"],"prefix":"10.1093","volume":"16","author":[{"given":"Tabraiz A.","family":"Mohammed","sequence":"first","affiliation":[{"name":"a University of Wisconsin Hospital and Clinics, Madison, Wisconsin, USA;"},{"name":"d Departments of Medicine, University of Wisconsin, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle D.","family":"Holen","sequence":"additional","affiliation":[{"name":"b University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA;"},{"name":"d Departments of Medicine, University of Wisconsin, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Jaskula-Sztul","sequence":"additional","affiliation":[{"name":"c Departments of Surgery, University of Wisconsin, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Mulkerin","sequence":"additional","affiliation":[{"name":"b University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA;"},{"name":"d Departments of Medicine, University of Wisconsin, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam J.","family":"Lubner","sequence":"additional","affiliation":[{"name":"b University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA;"},{"name":"d Departments of Medicine, University of Wisconsin, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Schelman","sequence":"additional","affiliation":[{"name":"b University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA;"},{"name":"d Departments of Medicine, University of Wisconsin, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Eickhoff","sequence":"additional","affiliation":[{"name":"e Departments of Biostatistics and Medical Informatics, University of Wisconsin, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Chen","sequence":"additional","affiliation":[{"name":"b University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA;"},{"name":"c Departments of Surgery, University of Wisconsin, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelle K.","family":"LoConte","sequence":"additional","affiliation":[{"name":"b University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA;"},{"name":"d Departments of Medicine, University of Wisconsin, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,5,31]]},"reference":[{"key":"2021122303434519800_B1","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/9781444300222.ch57","article-title":"Classification of Neuroendocrine Tumors","volume-title":"Clinical Endocrine Oncology","author":"Ansari","year":"2008","edition":"Second Edition"},{"key":"2021122303434519800_B2","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1634\/theoncologist.2007-0239","article-title":"Current management of medullary thyroid cancer","volume":"13","author":"Sippel","year":"2008","journal-title":"The Oncologist"},{"key":"2021122303434519800_B3","first-page":"187","article-title":"Gastrointestinal neuroendocrine tumors","volume":"178","author":"Delcore","year":"1994","journal-title":"J Am Coll Surg"},{"key":"2021122303434519800_B4","first-page":"1065","volume-title":"Cancer Treatment","author":"Pisegna","year":"2001"},{"issue":"Suppl 1","key":"2021122303434519800_B5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000051851","article-title":"Biological and molecular aspects of gastroenteropancreatic neuroendocrine tumors","volume":"62","author":"Rindi","year":"2000","journal-title":"Digestion"},{"issue":"Suppl 1","key":"2021122303434519800_B6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000080731","article-title":"Epidemiology of neuroendocrine tumours","volume":"80","author":"Taal","year":"2004","journal-title":"Neuroendocrinology"},{"key":"2021122303434519800_B7","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122303434519800_B8","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1634\/theoncologist.2008-0207","article-title":"Carcinoid tumors","volume":"13","author":"Pinchot","year":"2008","journal-title":"The Oncologist"},{"key":"2021122303434519800_B9","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/cncr.11105","article-title":"A 5-decade analysis of 13,715 carcinoid tumors","volume":"97","author":"Modlin","year":"2003","journal-title":"Cancer"},{"key":"2021122303434519800_B10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00384-006-0145-2","article-title":"Rare tumors of the colon and rectum: a national review","volume":"22","author":"Kang","year":"2007","journal-title":"Int J Colorectal Dis"},{"key":"2021122303434519800_B11","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/978-1-4615-6165-1_12","article-title":"Advances in the diagnosis and treatment of gastrointestinal neuroendocrine tumors","volume":"90","author":"Lee","year":"1997","journal-title":"Cancer Treat Res"},{"issue":"Suppl 2","key":"2021122303434519800_B12","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1093\/annonc\/12.suppl_2.S111","article-title":"Chemotherapy and biotherapy in the treatment of neuroendocrine tumours","volume":"12","author":"Oberg","year":"2001","journal-title":"Ann Oncol"},{"key":"2021122303434519800_B13","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122303434519800_B14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1756-9966-29-19","article-title":"Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives","volume":"29","author":"Appetecchia","year":"2010","journal-title":"J Exp Clin Cancer Res"},{"key":"2021122303434519800_B15","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2005.03.038","article-title":"Current status of gastrointestinal carcinoids","volume":"128","author":"Modlin","year":"2005","journal-title":"Gastroenterology"},{"key":"2021122303434519800_B16","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0039-6109(05)70141-9","article-title":"Islet cell tumors of the pancreas: the medical oncologist's perspective","volume":"81","author":"Brentjens","year":"2001","journal-title":"Surg Clin North Am"},{"key":"2021122303434519800_B17","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1056\/NEJM199202203260804","article-title":"Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma","volume":"326","author":"Moertel","year":"1992","journal-title":"N Engl J Med"},{"key":"2021122303434519800_B18","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/(SICI)1097-0142(19990915)86:6<944::AID-CNCR8>3.0.CO;2-P","article-title":"Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma","volume":"86","author":"Cheng","year":"1999","journal-title":"Cancer"},{"key":"2021122303434519800_B19","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.1158\/1078-0432.CCR-04-0422","article-title":"Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors","volume":"10","author":"Shah","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2021122303434519800_B20","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/01.COC.0000054535.19808.F4","article-title":"Topotecan in patients with advanced neuroendocrine tumors: a phase II study with significant hematologic toxicity","volume":"27","author":"Ansell","year":"2004","journal-title":"Am J Clin Oncol"},{"key":"2021122303434519800_B21","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/cncr.20466","article-title":"A Phase II trial of gemcitabine for metastatic neuroendocrine tumors","volume":"101","author":"Kulke","year":"2004","journal-title":"Cancer"},{"key":"2021122303434519800_B22","first-page":"4000","article-title":"Updated safety and efficacy results of the phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of pancreatic neuroendocrine tumors (NET)","volume":"28","author":"Niccoli","year":"2010","journal-title":"ASCO Meeting Abstracts"},{"key":"2021122303434519800_B23","first-page":"49","article-title":"Role of chemotherapy in gastro-entero-pancreatic neuroendocrine tumors: the end of a story?","volume":"72","author":"Delaunoit","year":"2009","journal-title":"Acta Gastroenterol Belg"},{"key":"2021122303434519800_B24","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nrc1186","article-title":"The role of Notch in tumorigenesis: oncogene or tumour suppressor?","volume":"3","author":"Radtke","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"2021122303434519800_B25","doi-asserted-by":"crossref","first-page":"G636","DOI":"10.1152\/ajpgi.00146.2005","article-title":"Conservation of the Notch1 signaling pathway in gastrointestinal carcinoid cells","volume":"289","author":"Kunnimalaiyaan","year":"2005","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2021122303434519800_B26","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.surg.2005.05.027","article-title":"Hairy Enhancer of Split-1 (HES-1), a Notch1 effector, inhibits the growth of carcinoid tumor cells","volume":"138","author":"Kunnimalaiyaan","year":"2005","journal-title":"Surgery"},{"key":"2021122303434519800_B27","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1210\/jc.2005-0540","article-title":"Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by notch signaling","volume":"90","author":"Nakakura","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122303434519800_B28","doi-asserted-by":"crossref","first-page":"39819","DOI":"10.1074\/jbc.M603578200","article-title":"Overexpression of the NOTCH1 intracellular domain inhibits cell proliferation and alters the neu-roendocrine phenotype of medullary thyroid cancer cells","volume":"281","author":"Kunnimalaiyaan","year":"2006","journal-title":"J Biol Chem"},{"key":"2021122303434519800_B29","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1634\/theoncologist.12-5-535","article-title":"Tumor Suppressor Role of Notch-1 Signaling in Neuroendocrine Tumors","volume":"12","author":"Kunnimalaiyaan","year":"2007","journal-title":"Oncologist"},{"key":"2021122303434519800_B30","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1634\/theoncologist.12-8-942","article-title":"Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells","volume":"12","author":"Greenblatt","year":"2007","journal-title":"The Oncologist"},{"issue":"Suppl 2","key":"2021122303434519800_B31","first-page":"5","article-title":"The history of valproate in clinical neuroscience","volume":"37","author":"Henry","year":"2003","journal-title":"Psychopharmacol Bull"},{"key":"2021122303434519800_B32","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.surg.2008.08.027","article-title":"Histone deacetylase inhibitors upregulate Notch-1 and inhibit growth in pheochromocytoma cells","volume":"144","author":"Adler","year":"2008","journal-title":"Surgery"},{"key":"2021122303434519800_B33","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1634\/theoncologist.2007-0190","article-title":"Suberoyl bis-hydroxamic acid activates Notch-1 signaling and induces apoptosis in medullary thyroid carcinoma cells","volume":"13","author":"Ning","year":"2008","journal-title":"The Oncologist"},{"key":"2021122303434519800_B34","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"2021122303434519800_B35","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1038\/ajg.2010.154","article-title":"Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors","volume":"105","author":"Massironi","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"2021122303434519800_B36","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1159\/000152000","article-title":"Chromogranin a levels in diagnosis, treatment and follow-up of 42 patients with non-functioning pancreatic endocrine tumours","volume":"8","author":"Nikou","year":"2008","journal-title":"Pancreatology"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2011-0031","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2011-0031","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/16\/6\/835\/41853768\/oncolo_16_6_835.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/16\/6\/835\/41853768\/oncolo_16_6_835.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T01:50:15Z","timestamp":1640224215000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/16\/6\/835\/6401066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,31]]},"references-count":36,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2011,5,31]]},"published-print":{"date-parts":[[2011,6,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2011-0031","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.12968956.14275054","asserted-by":"object"}]},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,6,1]]},"published":{"date-parts":[[2011,5,31]]}}}